Skip to main content

Advertisement

SpringerLink
Log in

Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The objective of the study was to analyze the impact of TNF antagonists (TNFa) on the total cholesterol and triglycerides on ankylosing spondylitis (AS) and psoriatic arthritis (PsA). In this single-centre observational study of AS and PsA patients, differences in triglyceride and total cholesterol levels and frequency of hypertriglyceridemia and hypercholesterolemia at 3 and 6 months were analysed in patients treated and not treated with TNFa. General estimation equations and linear regression analysis were used to investigate associations between disease activity and lipid levels and to identify predictors of change. One hundred fifty-seven patients treated, and 157 not treated with TNFa, were included in the study. A transient increase in cholesterol level from baseline to 3 months in TNFa-treated patients was the only statistically significant effect (P < 0.001). Persistent percentages of hypertriglyceridemia and hypercholesterolemia from baseline were significantly higher in not treated than in TNFa-treated patients (P = 0.009 and P = 0.001, respectively). Inverse associations between changes in cholesterol level and Bath Ankylosing Spondylitis Disease Activity Index (P = 0.011) and CRP (P < 0.001), but not Disease Activity Score in 28 Joints (P = 0.095) were found in the whole group. In AS and PsA patients treated with TNFa, mild and transient changes in cholesterol but not in triglyceride levels were associated with changes in disease activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921–1925. doi:10.1136/ard.2011.151191

    Article  PubMed  Google Scholar 

  2. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68(7):1131–1135. doi:10.1136/ard.2008.094839

    Article  CAS  PubMed  Google Scholar 

  3. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44(12):2737–2745

    Article  PubMed  Google Scholar 

  4. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ (2005) Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 52(8):2293–2299. doi:10.1002/art.21204

    Article  CAS  PubMed  Google Scholar 

  5. Daien CI, Duny Y, Barnetche T, Daures JP, Combe B, Morel J (2012) Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71(6):862–868. doi:10.1136/annrheumdis-2011-201148

    Article  CAS  PubMed  Google Scholar 

  6. Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gomez-Reino JJ (2014) Lipid profile changes in patients with chronic inflammatory arthritis treated with biologics and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis & rheumatology (Hoboken, NJ). doi:10.1002/art.38894

  7. Mathieu S, Dubost JJ, Tournadre A, Malochet-Guinamand S, Ristori JM, Soubrier M (2010) Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint, bone, spine : revue du rhumatisme 77(1):50–52. doi:10.1016/j.jbspin.2009.05.012

    Article  CAS  Google Scholar 

  8. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA (2006) Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33(5):921–923

    CAS  PubMed  Google Scholar 

  9. van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, van der Horst-Bruinsma IE, Hazenberg BP, van de Stadt RJ, Wolbink GJ, Nurmohamed MT (2009) Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 60(5):1324–1330. doi:10.1002/art.24492

    Article  PubMed  Google Scholar 

  10. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147(8):573–577

    Article  Google Scholar 

  11. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368

    Article  PubMed  Google Scholar 

  12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. doi:10.1002/art.21972

    Article  PubMed  Google Scholar 

  13. Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BA, Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT (2007) Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 66(7):958–961. doi:10.1136/ard.2006.059691

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Feingold KR, Spady DK, Pollock AS, Moser AH, Grunfeld C (1996) Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J Lipid Res 37(2):223–228

    CAS  PubMed  Google Scholar 

  15. Fried SK, Zechner R (1989) Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J Lipid Res 30(12):1917–1923

    CAS  PubMed  Google Scholar 

  16. Memon RA, Grunfeld C, Moser AH, Feingold KR (1993) Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 132(5):2246–2253. doi:10.1210/endo.132.5.8477669

    CAS  PubMed  Google Scholar 

  17. Horie M, Noguchi S, Tanaka W, Goto Y, Yoshihara H, Kawakami M, Suzuki M, Sakamoto Y (2013) Relationships among smoking habits, airflow limitations, and metabolic abnormalities in school workers. PLoS One 8(11):e81145. doi:10.1371/journal.pone.0081145

    Article  PubMed  PubMed Central  Google Scholar 

  18. Yoo WH (2004) Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 31(9):1746–1753

    PubMed  Google Scholar 

Download references

Contributors

J.R.M.: conception and study design, data collection, interpretation of data, and drafting the article. A.S: conception and study design, data collection, and interpretation of data. J.J.GR: study design, interpretation of data, drafting the article, and revising it critically for important intellectual content. All authors gave final approval of the version to be published.

Author information

Authors and Affiliations

  1. Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, c/ Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain

    Jose Ramon Maneiro, Alejandro Souto & Juan J. Gomez-Reino

  2. Fundación Ramón Domínguez, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain

    Jose Ramon Maneiro, Alejandro Souto & Juan J. Gomez-Reino

Authors
  1. Jose Ramon Maneiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alejandro Souto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan J. Gomez-Reino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose Ramon Maneiro.

Ethics declarations

This study was approved by the Clinical Research Ethics Committee of Galicia, Spain.

Competing interest

J.J. G-R. is on the Advisory Boards of Abbvie, BMS, Hospira, Jansen, MSD, Pfizer, Roche, and UCB SA; has received lecture fees from Abbvie, BMS, Pfizer, Roche, and MSD; and has received research grants from Pfizer, MSD, and Roche. Other authors have declared no conflicts of interest.

Funding

This work was supported by an unrestricted grant from Pfizer. The funding source had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Electronic supplementary material

ESM 1

(DOCX 13 kb)

ESM 2

(DOCX 14 kb)

ESM 3

(DOCX 14 kb)

ESM 4

(DOCX 14 kb)

ESM 5

(DOCX 14 kb)

ESM 6

(DOCX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maneiro, J.R., Souto, A. & Gomez-Reino, J.J. Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis. Clin Rheumatol 36, 1167–1172 (2017). https://doi.org/10.1007/s10067-017-3537-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3537-5

Keywords

Search

Navigation